«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2012年第6期

页码:

773-776

栏目:

综述

出版日期:

2012-12-25

文章信息/Info

Title:

Research progress of congenital heart disease with pulmonary arterial hypertension

作者:

李召峰¹; 2综述; 王齐兵¹; 葛均波¹审阅

(1.复旦大学附属中山医院心内科，上海 200032；2.解放军第88医院心内科，山东 泰安 271000)

Author(s):

LI Zhao-feng¹; 2;  WANG Qi-bing¹;  GE Jun-bo¹

(1.Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China; 2.Department of Cardiology, PLA 88 Hospital, Tai’an 271000, Shandong, China)

关键词:

心脏病; 先天性; 肺动脉高压

Keywords:

congenital heart disease;  pulmonary arterial hypertension

分类号:

R541.1

DOI:

-

文献标识码:

A

摘要:

由于先天性心脏病（先心病）并发肺动脉高压（PAH）患者的死亡率和致残率均较高，人们重新审视了先心病并发PAH的流行病学特征及分类，并探索新的治疗手段，发掘新的能够反映PAH严重程度及预后的生物学标志物，为先心病并发PAH诊治水平的提高开辟了广阔的前景。

Abstract:

Due to the high rates of mortality and morbidity of patients with congenital heart disease (CHD) with pulmonary arterial hypertension (PAH), the epidemiological characteristics and classification of CHD with PAH were reassessed by many CHD experts. In recent years, some new treatments and screening biomarkers, which may be used to reflect the severity and outcome endpoint of CHD patients with PAH, have been further explored. These results offer the possibility of improving diagnosis and treatment of CHD with PAH.

参考文献/References

[1]Adatia I,Kothari SS,Feinstein JA.Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease:the global perspective[J].Chest,2010,137(6 Suppl):52S-61S.
[2] Engelfriet PM, Duffels MG, Moller T,et al.Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease[J].Heart,2007,93(6):682-687.
[3]McLaughlin VV,Archer SL,Badesch DB,et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association[J].J Am Coll Cardiol,2009,53(17):1573-1619.
[4]Badesch DB,Champion HC,Sanchez MA,et al.Diagnosis and assessment of pulmonary arterial hypertension[J].J Am Coll Cardiol,2009,54 (1 Suppl):S55-S66.
[5]Simonneau G,Robbins IM,Beghetti M,et al.Updated clinical classifi cation of pulmonary hypertension[J].J Am Coll Cardiol,2009,54(1 suppl):S43-S54.
[6]Diller GP,Baumgartner H.Pulmonary arterial hypertension in adults with congenital heart disease[J].Int J Clin Pract Suppl,2010,165 (Suppl.165):13-24.
[7]Dupuis J,Hoeper MM.Endothelin receptor antagonists in pulmonary arterial hypertension[J].Eur Respir J,2008,31(2):407-415.
[8]McLaughlin VV,Archer SL,Badesch DB,et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension.a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society,Inc.and the Pulmonary Hypertension Association[J].J Am Coll Cardiol,2009,53(17):1573-1619.
[9]Kulik T,Mullen M,Adatia I. Pulmonary arterial hypertension associated with congenital heart disease[J].Progress Pediatric Cardiology,2009,27(1-2):25-33.
[10]Nef HM,Mollmann H,Hamm C,et al.Pulmonary hypertension:updated classification and management of pulmonary hypertension[J].Heart,2010, 96(7):552-559.
[11]Apostolopoulou SC,Manginas A,Cokkinos DV,et al.Long-term oral bosentan treatment in patientswith pulmonary arterial hypertension related to congenital heart disease:a 2-year study[J].Heart,2007,93(3):350-354.
[12]Archer SL,Michelakis ED.Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension[J].N Engl J Med,2009,361(19):1864-1871.
[13]Wilkins MR,Ali O,Bradlow W,et al.Simvastatin as a treatment for pulmonary hypertension trial[J].Am J Respir Crit Care Med,2010,181(10):1106-1113.
[14]Diller GP,van Eijl S,Okonko DO,et al.Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension[J].Circulation,2008,117(23):3020-3030.
[15] Nagaya N,Nishikimi T,Uematsu M,et al.Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension[J].Circulation,2000,102(8):865-870.
[16]Heresi GA.Clinical perspective:biomarkers in pulmonary arterial hypertension[J].Int J Clin Pract Suppl, 2011,(169):5-7.

备注/Memo

备注/Memo:

收稿日期：2012-03-26.作者简介：李召峰，主治医师，博士 Email:lizhaofeng_1978@yahoo.com.cn

常用功能

更新日期/Last Update: 2012-12-30